Clinical trials: Amyloid Beta-protein
Amyloid Beta Protein
Escitalopram Effects on CSF Amyloid Beta
Alzheimers disease (AD) is a devastating illness, estimated to affect 5 million patients in the United States alone and projected to increase dramatically over the next decades as the population ages unless preventive measures…
- Trial name
- NCT02161458
- Testing
- Escitalopram 20mg for 2 weeks, Escitalopram 20mg for 8 weeks, Escitalopram 30mg for 8 weeks
- Where
- 2 sites in United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Alzheimer s Disease, Major Depressive Disorder (MDD)
VR Pupillometry in Cognitive Impairment
With disease-modifying therapies emerging for dementia and related conditions, identifying cognitive decline as early as possible is increasingly important.
- Conditions
- Alzheimer s Disease, Major Depressive Disorder (MDD), Mild Cognitive Impairment, Dementia
- Trial name
- NCT07402356
- Where
- Germany
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Max-Planck-Institute of Psychiatry
Alzheimer's Disease
Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease
The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I MNI-388 and MNI 390, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed…
- Trial name
- NCT00886951
- Testing
- I123MNI388/I123MNI390
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Alzheimer's Disease
Study to Evaluate Safety, Tolerability and Immunogenicity of Vaccine (UB 311) in Subjects With Alzheimer's Disease
The purpose of this Phase I study is to determine whether the vaccine (UB 311), targeting the amyloid beta peptide (N-terminal amino acids, 1-14), is safe and immunogenic in patients diagnosed with mild or moderate Alzheimer's…
- Trial name
- NCT00965588
- Testing
- UB 311
- Where
- 2 sites in Taiwan
- Volunteers
- 19 people
- Sponsor
- United Biomedical
Alzheimers Disease
Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects
The underlying goal of this study is to assess 123-I AV39 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of AD research participants and age- and gender-matched healthy subjects.
- Trial name
- NCT00439010
- Testing
- [123I] AV 39
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Familial Cold Urticaria
The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria
An open labelled trial of Kineret (anakinra) induction therapy (100mg./day) in over a four week period in the treatment of Familial Cold Urticaria.
- Trial name
- NCT00214851
- Testing
- Kineret (anakinra)
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- Nova Scotia Health Authority
Alzheimer's Disease
A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's
The purpose of this trial is to compare the average change in the amount of amyloid beta species in blood after an infusion of solanezumab.
- Trial name
- NCT01148498
- Testing
- solanezumab
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Elderly Individuals Aged 60 Years or Older, Mild Cognitive Impairment (MCI)
THE EFFECTS OF GAMBIR CATECHIN (UNCARIA GAMBIR ROXB) SUPPLEMENTATION ON COGNITIVE FUNCTION, EXPRESSION OF APP, MAPT, BDNF, IL-10, TGF-Β GENES, AND PLASMA MDA LEVELS IN THE ELDERLY.
Objective The primary objective of this clinical trial is to investigate the effects of gambir catechin administration on cognitive function, the expression of amyloid precursor protein (APP), microtubule-associated protein tau…
- Trial name
- NCT06604390
- Testing
- catechin extracts (health food), plasebo
- Where
- 2 sites in Fiji, Indonesia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Rahmi Novita Yusuf
Alzheimer's Disease
Genistein as a Possible Treatment for Alzheimer's Disease.
Genistein is an isoflavone that has antioxidant and neuroprotective effects on Alzheimer's disease (AD). A few years ago our group reported that genistein increased PPARg (peroxisome proliferator activated receptor gamma) levels.
- Trial name
- GENIAL (NCT01982578)
- Testing
- Genistein
- Where
- 2 sites in Spain
- Volunteers
- 27 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Alzheimer's Disease
Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease
The overall goal of this double-blind Phase II study is to evaluate the safety, efficacy and biological mechanisms of action of Intravenous Immunoglobulin (IVIg) in the treatment of mild to moderate stage Alzheimer's disease…
- Trial name
- NCT00299988
- Testing
- Intravenous Immunoglobulin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Weill Medical College of Cornell University
Alzheimer's Disease (AD)
Prospective Single-Arm Safety Study of Cervical LVA in AD Patients
Official Title Prospective Single-Arm Safety Study of Cervical Lymphaticovenular Anastomosis (LVA) in Patients with Alzheimer's Disease Purpose of the Study Researchers are conducting this study to see if a minimally invasive…
- Trial name
- Neck LVA (NCT07458620)
- Testing
- Supermicrosurgical Lymphaticovenular Anastomosis (LVA)
- Where
- Taiwan
- Volunteers
- 35 people
- Sponsor
- Chang Gung Memorial Hospital
Parkinson Disease
Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease
This Parkinson disease (PD) trial will test whether 26 months of citalopram, compared to placebo, can alter the build-up of toxic amyloid-beta plaques in the visuospatial cortex of the brain linked to visuospatial cognitive…
- Trial name
- NCT04497168
- Testing
- Citalopram 20mg
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- University of Michigan
Alzheimer Disease, Amyloid Beta-Protein
Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients
The aim of the study is to investigate whether Florbetaben (BAY94-9172)positron emission tomography (PET) is able to distinguish between subjects with mild cognitive impairment (MCI) progressing to Alzheimer's disease (AD) from…
- Trial name
- NCT01138111
- Testing
- Florbetaben (BAY94-9172)
- Where
- Australia
- Volunteers
- 45 people
- Sponsor
- Lantheus Biosciences Ltd.
Alzheimer Disease
A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.
To test that LY450139, a gamma-secretase inhibitor, will reduce the rate of newly synthesize Amyloid Beta by determining the amount of newly synthesized 13C6 leucine-labeled Amyloid Beta in lumbar cerebrospinal fluid from…
- Trial name
- NCT00765115
- Testing
- LY450139
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer Disease
Effect of Lithium and Divalproex in Alzheimer's Disease
This study will examine the effect of the drugs lithium and divalproex (Depakote) on tau proteins, a type of protein in the brain and spinal fluid that are altered in patients with Alzheimer's disease.
- Trial name
- NCT00088387
- Testing
- Divalproex, Lithium
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Preclinical Alzheimer's Disease, Alzheimer Disease
AV-1959R Vaccine in Individuals With Preclinical Alzheimer's Disease
This Phase 2 study will evaluate the safety, tolerability, immunogenicity, and amyloid-lowering effect of AV-1959R in cognitively unimpaired adults with preclinical Alzheimer's disease.
- Trial name
- AREVIA (NCT07827768)
- Testing
- AV-1959R
- Volunteers
- 160 people
- Sponsor
- Institute for Molecular Medicine
Obstructive Sleep Apnea, Alzheimer's Disease
Brain Sleep Clearance of Amyloid-Beta Peptides
The 'Amyloid Cascade Hypothesis' posits that the accumulation of a peptide, amyloid beta (Aβ), in the brain is the initiating event in Alzheimer's disease (AD), however, the mechanisms involved are not well understood.
- Trial name
- Brain SCRAPs (NCT02474251)
- Testing
- Continuous positive airway pressure device
- Where
- 2 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Alzheimer Disease
Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain
This research is designed to obtain efficacy and safety information for 123-I IMPY as an imaging biomarker for Alzheimer's disease (AD).
- Trial name
- NCT00287248
- Testing
- [123I] IMPY & SPECT Imaging
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Alzheimer's Disease (AD)
Phase 1 Study to Evaluate the Safety and Tolerability of 8M2D in Healthy People and Alzheimer's Patients
This study is testing a new investigational drug called 8M2D to learn whether it is safe and well-tolerated in humans. 8M2D has not previously been given to people.
- Trial name
- NCT07568041
- Testing
- 8M2D
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Cenna Biosciences Inc.
Alzheimer Disease
The Effect of Short-Term Statins and NSAIDs on Levels of Beta-Amyloid, a Protein Associated With Alzheimer's Disease
The purpose of this study is to determine whether short-term use of the drugs ibuprofen and lovastatin affects levels of a protein called beta-amyloid in people who are at risk for developing Alzheimer's Disease (AD).
- Trial name
- NCT00046358
- Testing
- Lovostatin, Ibuprofen
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)